Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy

PURPOSE: Doxorubicin/cyclophosphamide followed by docetaxel chemotherapy (AC-D) is an intermediate risk factor (incidence of 10%–20%) for febrile neutropenia (FN) in breast cancer. However, the reported incidence of FN while using this regimen was obtained mostly from Western breast cancer patients,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Breast Cancer
Main Authors: Kim, Chang Gon, Sohn, Joohyuk, Chon, Hongjae, Kim, Joo Hoon, Heo, Su Jin, Cho, Hyunsoo, Kim, In Jung, Kim, Seung Il, Park, Seho, Park, Hyung Seok, Kim, Gun Min
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Breast Cancer Society 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4822110/
https://ncbi.nlm.nih.gov/pubmed/27064666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4048/jbc.2016.19.1.76
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados